SciSparc (SPRC) Competitors $2.72 -0.31 (-10.33%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. DWTX, BFRI, APRE, KPRX, ENTO, TLPH, EVOK, CLDI, MTNB, and SNOAShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Dogwood Therapeutics (DWTX), Biofrontera (BFRI), Aprea Therapeutics (APRE), Kiora Pharmaceuticals (KPRX), Entero Therapeutics (ENTO), Talphera (TLPH), Evoke Pharma (EVOK), Calidi Biotherapeutics (CLDI), Matinas Biopharma (MTNB), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Dogwood Therapeutics Biofrontera Aprea Therapeutics Kiora Pharmaceuticals Entero Therapeutics Talphera Evoke Pharma Calidi Biotherapeutics Matinas Biopharma Sonoma Pharmaceuticals SciSparc (NASDAQ:SPRC) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Do analysts recommend SPRC or DWTX? Dogwood Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 102.27%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in SPRC or DWTX? 25.1% of SciSparc shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SPRC or DWTX? SciSparc has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Which has higher earnings & valuation, SPRC or DWTX? SciSparc has higher revenue and earnings than Dogwood Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.31M1.10-$6.28MN/AN/ADogwood TherapeuticsN/AN/A-$12.35M-$18.78-0.26 Does the media refer more to SPRC or DWTX? In the previous week, SciSparc had 7 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 8 mentions for SciSparc and 1 mentions for Dogwood Therapeutics. SciSparc's average media sentiment score of 0.72 beat Dogwood Therapeutics' score of 0.60 indicating that SciSparc is being referred to more favorably in the media. Company Overall Sentiment SciSparc Positive Dogwood Therapeutics Positive Is SPRC or DWTX more profitable? Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Dogwood Therapeutics N/A N/A -27.41% SummarySciSparc beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41M$2.49B$5.77B$9.79BDividend YieldN/A1.68%3.95%4.02%P/E RatioN/A22.8231.2726.59Price / Sales1.10541.05440.26156.12Price / CashN/A177.0937.7359.36Price / Book0.156.1810.616.68Net Income-$6.28M$32.94M$3.27B$265.59M7 Day Performance-41.32%-0.78%1.41%0.62%1 Month Performance-59.39%2.77%6.20%2.61%1 Year Performance-64.93%12.01%50.13%22.34% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc1.0456 of 5 stars$2.72-10.3%N/A-66.0%$1.41M$1.31M0.004News CoverageGap DownDWTXDogwood Therapeutics1.6644 of 5 stars$4.98-6.0%$10.00+100.8%N/A$9.51MN/A-0.275Gap UpBFRIBiofrontera3.096 of 5 stars$0.93flat$2.75+195.7%-16.5%$9.43M$37.32M-0.4170Gap DownAPREAprea Therapeutics3.2409 of 5 stars$1.59-3.6%$15.50+874.8%-54.7%$9.27M$1.50M-0.697News CoverageGap UpKPRXKiora Pharmaceuticals3.5438 of 5 stars$2.69-6.6%$10.00+271.7%-25.9%$9.23M$16.02M-0.9210ENTOEntero TherapeuticsN/A$1.93-10.6%N/A+70.6%$9.21MN/A0.009Gap DownTLPHTalphera2.7207 of 5 stars$0.45+3.6%$5.00+1,016.1%-41.9%$9.18M$650K-1.1219Gap DownHigh Trading VolumeEVOKEvoke Pharma0.6975 of 5 stars$6.13+2.9%N/A+20.3%$9.15M$12.79M-2.394Gap DownCLDICalidi Biotherapeutics1.5257 of 5 stars$3.00-26.8%N/A-87.6%$9.08MN/A0.0038Positive NewsGap UpMTNBMatinas Biopharma0.6437 of 5 stars$1.70-0.6%N/AN/A$8.65MN/A-0.3530SNOASonoma PharmaceuticalsN/A$5.23-2.2%N/A+2,702.7%$8.59M$14.91M-2.13180Gap Down Related Companies and Tools Related Companies DWTX Alternatives BFRI Alternatives APRE Alternatives KPRX Alternatives ENTO Alternatives TLPH Alternatives EVOK Alternatives CLDI Alternatives MTNB Alternatives SNOA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access